Liver disease and poor adherence limit hepatitis C cure : a real-world Australian treatment cohort

P.J. Clark, P.C. Valery, S.I. Strasser, M. Weltman, A.J. Thompson, M. Levy, B. Leggett, A. Zekry, J. Rong, P. Angus, J. George, S. Bollipo, Bruce McGarity, W. Sievert, G. Macquillan, E. Tse, A. Nicoll, A. Wade, G. Chu, D. HardingW. Cheng, G. Farrell, S.K. Roberts

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aims: In 2016, direct-acting antiviral (DAA) treatment for hepatitis C (HCV) became available through Australia’s universal health care system, with the aim of HCV elimination. We report real-world effectiveness of DAA HCV treatment in Australia from a clinically well-informed cohort, enriched for cirrhosis and prior HCV treatment. Methods: 3413 patients were recruited from 26 hospital liver clinics across Australia from February 2016 to June 2020. Clinical history and sustained viral response (SVR) were obtained from medical records and data linkage to the Australian Pharmaceutical Benefits Scheme. Factors associated with SVR were assessed by multivariable logistic regression (MVR). Results: At recruitment, 32.2% had cirrhosis (72.9% Child Pugh class B/C), and 19.9% were treatment experienced. Of the 2,939 with data, 93.3% confirmed SVR. 137 patients received second-line therapy. Patients with cirrhosis had lower SVR rate (88.4 vs. 95.8%; p < 0.001). On MVR, failure to achieve SVR was associated with Genotype 3 (adj-OR = 0.42, 95%CI 0.29–0.61), male gender (adj-OR = 0.49, 95%CI 0.31–0.77), fair/poor adherence (adj-OR = 0.52, 95%CI 0.28–0.94), cirrhosis (adj-OR = 0.57, 95%CI 0.36–0.88), FIB-4 > 3.25 (adj-OR = 0.52, 95%CI 0.33–0.83) and MELD score ≥ 20 (adj-OR = 0.25, 95%CI 0.08–0.80). Consistent results were seen in cirrhotic sub-analysis. Conclusions: Excellent SVR rates were achieved with DAAs in this real-world cohort of patients with chronic HCV infection. More advanced liver disease and clinician impression of poor adherence were associated with HCV treatment failure. Supports to improve liver fibrosis assessment skills for non-specialist DAA prescribers in the community and to optimize patient adherence are likely to enable more effective pursuit of HCV elimination in Australia.
Original languageEnglish
Pages (from-to)291-303
Number of pages13
JournalDigestive Diseases and Sciences
Volume68
Issue number1
DOIs
Publication statusPublished - Jan 2023

Open Access - Access Right Statement

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Fingerprint

Dive into the research topics of 'Liver disease and poor adherence limit hepatitis C cure : a real-world Australian treatment cohort'. Together they form a unique fingerprint.

Cite this